Handicapping lame duck biopharma provisions 

As legislators, lobbyists and congressional staff scramble to get legislation enacted before the 117th Congress, the biopharma industry, patient advocates and FDA are in the scrum. Only provisions that have bipartisan support in both houses of Congress during the remaining weeks of this congressional session will become law.

For biopharma, the list will mostly be drawn from the Food and Drug Amendments of 2022 (H.R. 7667), which the House passed earlier this year, as well as companion legislation endorsed by the Senate Health, Education, Labor and Pensions Committee. Some provisions that were in both bills, such as reform of the accelerated approval pathway and steps that are intended to increase clinical trials diversity, are very likely to make it into law this year. ...